Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment

Clinical Lung Cancer

Volumn 18, Issue 6, 2017, Pages 692-697

  Bordi, Paola ^a   Tiseo, Marcello ^a   Rofi, Eleonora ^b   Petrini, Iacopo ^b   Restante, Giuliana ^b   Danesi, Romano ^b   Del Re, Marzia ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

ALK; Circulating cell free DNA; Crizotinib resistance; KRAS; NSCLC

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; BRIGATINIB; CARBOPLATIN; CERITINIB; CRIZOTINIB; DNA; K RAS PROTEIN; PACLITAXEL; CIRCULATING TUMOR DNA; KRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN P21; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL ARTICLE; CODON; DNA EXTRACTION; DROPLET DIGITAL POLYMERASE CHAIN REACTION; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; POINT MUTATION; SYSTEMIC THERAPY; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY; BIOPSY; DISEASE EXACERBATION; DRUG RESISTANCE; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CIRCULATING TUMOR DNA; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 85020436544     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2017.04.013     Document Type: Article

References (19)

1. Shaw, A.T., Solomon, B., Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 17 (2011), 2081–2086.
2. Solomon, B.J., Mok, T., Kim, D.W., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 (2014), 2167–2177.
3. Shaw, A.T., Kim, D.W., Nakagawa, K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 (2013), 2385–2394.
4. Gainor, J.F., Dardaei, L., Yoda, S., et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6 (2016), 1118–1133.
5. Doebele, R.C., Pilling, A.B., Aisner, D.L., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non–small-cell lung cancer. Clin Cancer Res 18 (2012), 1472–1482.
6. Shaw, A.T., Kim, D.W., Mehra, R., et al. Ceritinib in ALK-rearranged non–small-cell lung cancer. N Engl J Med 370 (2014), 1189–1197.
7. Ou, S.H., Ahn, J.S., De Petris, L., et al. Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase II global study. J Clin Oncol 34 (2016), 661–668.
8. Gettinger, S.N., Bazhenova, L.A., Langer, C.J., et al. Activity and safety of brigatinib in ALK-rearranged non–small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol 17 (2016), 1683–1696.
9. Shaw, A.T., Friboulet, L., Leshchiner, I., et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 374 (2016), 54–61.
10. Bordi, P., Del Re, M., Danesi, R., Tiseo, M., Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non–small-cell lung cancer. Transl Lung Cancer Res 4 (2015), 584–597.
11. Johnson, A.C., Do, P., Richard, N., et al. Identification of I1171N resistance mutation in ALK-positive non–small-cell lung cancer tumor sample and circulating tumor DNA. Lung Cancer 99 (2016), 38–40.
12. Wang, Y., Tian, P.W., Wang, W.Y., et al. Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non–small-cell lung cancer by capture-based next-generation sequencing. Oncotarget 7 (2016), 65208–65217.
13. Combaret, V., Iacono, I., Bellini, A., et al. Detection of tumor ALK status in neuroblastoma patients using peripheral blood. Cancer Med 4 (2015), 540–550.
14. Del Re, M., Tiseo, M., Bordi, P., et al. Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget 8 (2017), 13611–13619.
15. Toyokawa, G., Seto, T., Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data. Oncol Res Treat 38 (2015), 291–298.
16. Friboulet, L., Li, N., Katayama, R., et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small-cell lung cancer. Cancer Discov 4 (2014), 662–673.
17. Zhang, S., Anjum, R., Squillace, R., et al. The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin Cancer Res 22 (2016), 5527–5538.
18. Mengoli, M.C., Barbieri, F., Bertolini, F., Tiseo, M., Rossi, G., K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: report of two cases and review of the literature. Lung Cancer 93 (2016), 55–58.
19. Azzato, E.M., Deshpande, C., Aikawa, V., et al. Rare complex mutational profile in an ALK inhibitor-resistant non–small-cell lung cancer. Anticancer Res 35 (2015), 3007–3012.